Immunic Historical Income Statement
| IMUX Stock | USD 1.27 0.06 4.96% |
Historical analysis of Immunic income statement accounts such as Other Operating Expenses of 54.8 M or Research Development of 87.4 M can show how well Immunic performed in making a profits. Evaluating Immunic income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Immunic's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Immunic latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunic is a good buy for the upcoming year.
Immunic |
About Immunic Income Statement Analysis
Immunic Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Immunic shareholders. The income statement also shows Immunic investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Immunic Income Statement Chart
Immunic Income Statement is one of the three primary financial statements used for reporting Immunic's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Immunic revenue and expense. Immunic Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Immunic's Research Development is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 5.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 105.5 K in 2024. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Immunic. It is also known as Immunic overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Immunic's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.At this time, Immunic's Research Development is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 5.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 105.5 K in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 66K | 1.0M | 3.1M | 3.2M | Interest Income | 66K | 1.0M | 3.1M | 3.2M |
Immunic income statement Correlations
Click cells to compare fundamentals
Immunic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunic income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 50K | 39K | 85K | 65.9M | 111K | 105.5K | |
| Interest Expense | 107K | 58K | 85K | 1.0M | 936.9K | 730.2K | |
| Other Operating Expenses | 37.0M | 49.0M | 91.7M | 86.5M | 99.2M | 54.8M | |
| Operating Income | (37.0M) | (49.0M) | (91.7M) | (119.5M) | (99.2M) | (94.3M) | |
| Ebit | (37.0M) | (49.0M) | (91.7M) | (119.5M) | (99.2M) | (94.3M) | |
| Research Development | 22.5M | 38.6M | 61.1M | 71.3M | 83.2M | 87.4M | |
| Ebitda | (37.0M) | (48.9M) | (91.6M) | (53.5M) | (99.1M) | (94.2M) | |
| Total Operating Expenses | 37.0M | 49.0M | 91.7M | 86.5M | 99.1M | 54.8M | |
| Income Before Tax | (34.9M) | (44.0M) | (92.9M) | (120.4M) | (93.6M) | (88.9M) | |
| Total Other Income Expense Net | 2.1M | 5.0M | (1.3M) | (919K) | 5.6M | 5.9M | |
| Net Income | (34.8M) | (44.0M) | (92.8M) | (154.3M) | (93.6M) | (88.9M) | |
| Income Tax Expense | (107K) | (58K) | (151K) | 33.9M | 39.0M | 40.9M | |
| Selling General Administrative | 14.5M | 10.3M | 13.3M | 15.3M | 16.0M | 14.0M | |
| Net Income From Continuing Ops | (34.9M) | (44.0M) | (92.9M) | (120.4M) | (93.6M) | (98.3M) | |
| Non Operating Income Net Other | 2.1M | 5.0M | (1.3M) | (919K) | (827.1K) | (785.7K) | |
| Net Income Applicable To Common Shares | (34.9M) | (44.0M) | (92.9M) | (120.4M) | (108.4M) | (102.9M) | |
| Net Interest Income | 107K | 58K | 66K | 1.0M | 3.1M | 3.2M | |
| Reconciled Depreciation | 50K | 39K | 85K | 77K | 111K | 105.5K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.